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ABSTRACT
Introduction: We evaluated the feasibility of laparoscopic
cytoreduction for primary advanced ovarian cancer.
Methods: All patients with presumed stage 3/4 primary
ovarian cancer underwent attempted laparoscopic cytore-
duction. All patients had CT evidence of omental metas-
tasis and ascites. A 5-port (5-mm) transperitoneal ap-
proach was used. A bilateral salpingo-oophorectomy,
supracervical hysterectomy, and omentectomy were per-
formed with PlasmaKinetic (PK) cutting forceps. A lapa-
roscopic 5-mm Argon-Beam Coagulator was used to co-
agulate tumor in the pelvis, abdominal peritoneum,
intestinal mesentery, and diaphragm.
Results: Nine of 11 cases (82%) were successfully de-
bulked laparoscopically without conversion to laparot-
omy. Median operative time was 2.5 hours, and median
blood loss was 275 mL. All tumors were debulked to 2
cm and 45% had no residual disease. Stages were 1–3B,
7–3C, and 1–4. Median length of stay was one day. Me-
dian VAS pain score was 4 (discomforting). Two of 11
patients (18%) had postoperative complications.
Conclusion: Laparoscopic cytoreduction was successful
and resulted in minimal morbidity. Because of our small
sample size, additional studies are needed.
Key Words: Ovarian cancer, Cytoreduction, Salpingo-
oophorectomy, Supracervical hysterectomy, Omentectomy.
INTRODUCTION
Advanced laparoscopic procedures are increasingly being
utilized as an alternative to laparotomy in gynecologic
surgery.1–3 A meta-analysis of 27 prospective randomized
trials has proven the benefits of laparoscopic compared
with abdominal gynecologic surgery: decreased pain, de-
creased surgical-site infections (decreased relative risk
80%), decreased hospital stay (2 days less), quicker return
to activity (2 weeks sooner), and fewer postoperative
adhesions (decreased 60%).4
Advanced laparoscopic procedures are also increasingly
being utilized as an alternative to laparotomy in gyneco-
logic oncology surgery. Laparoscopic-assisted vaginal
hysterectomy (LAVH) with lymphadenectomy has be-
come a standard treatment for endometrial cancer.5 Lapa-
roscopic and robotic radical hysterectomy is becoming
more widely utilized for the treatment of cervical cancer.1
Laparoscopic staging of early ovarian cancer and laparo-
scopic secondary cytoreductive surgery for recurrent ovar-
ian cancer has been described.3
We have previously reported on the feasibility of the
Maylard transverse incision compared with the standard
midline incision for cytoreductive surgery in primary ad-
vanced ovarian cancer in an attempt to decrease morbid-
ity, ie, decreased postoperative pain, hernia rate, adhe-
sions, and pulmonary complications.6 Morbidity can be
further reduced by using laparoscopic surgery. Following
our laparoscopic success with endometrial cancer staging,
robotic radical hysterectomy,1 LAVH for leiomyoma
1000 g,2 and laparoscopic secondary cytoreduction for
recurrent ovarian cancer,3 we investigated laparoscopic
cytoreduction for primary stage 3/4 ovarian cancer.
The purpose of this study was to evaluate the feasibility of
laparoscopic cytoreduction for primary advanced ovarian
cancer.
MATERIALS AND METHODS
Over a 1-year period, all patients with presumed stage 3/4
primary ovarian cancer underwent attempted laparo-
scopic cytoreduction. All patients had evidence of omen-
tal metastasis and ascites on CT scan. No patients were
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SCIENTIFIC PAPERexcluded. Patients with microscopic abdominal metastasis
(stage 3A) and microscopic nodal metastasis were not
included because cytoreduction was not required. All pa-
tients were operated on by a single gynecologic oncolo-
gist and were identified retrospectively through his surgi-
cal log. Institutional review board approval was obtained.
All patients received a preoperative bowel prep with 45
mL of fleets phosphosoda orally, a single dose of preop-
erative prophylactic antibiotics and external pneumatic
cuffs.
All procedures were performed with the patient under
general endotracheal anesthesia. An orogastric tube was
inserted and removed at the end of surgery. The patient
was positioned in the dorsolithotomy position with legs in
Allen stirrups, and placed in a maximal Trendelenburg
position ( 30°). A gel pad was placed under the buttocks
to prevent the patient from gravitating towards the head of
the table. A 5-port (5-mm) transperitoneal approach was
used. A 5-mm trocar was inserted in the left upper quad-
rant and ascites was aspirated. Four additional 5-mm ports
were placed: periumbilical, right and left lower quadrant,
and right upper quadrant. Round ligaments were excised
with PlasmaKinetic (PK) cutting forceps (Gyrus ACMI,
Southborough, MA). Retroperitoneal spaces were dis-
sected, both ureters were identified, and the infundibu-
lopelvic ligaments were excised with the PK cutting for-
ceps. The anterior and posterior leaf of the broad ligament
was dissected, and the bladder was dissected off the
cervix with monopolar electrosurgery. Uterine vessels and
cardinal and uterosacral ligaments were then coagulated
and cut with the PK cutting forceps. A supracervical hys-
terectomy was completed by excising the upper endocer-
vix with the PK cutting forceps. The Trendelenburg posi-
tion was discontinued, and the omentum was retracted
toward the pelvis via graspers through the lower quadrant
ports. The lateral attachments of the infracolic omentum
were excised with the PK cutting forceps. If the omental
metastasis was not densely adherent to the transverse
colon, the entire omentectomy was performed with the
PK cutting forceps. A 6-cm periumbilical Maylard incision
was performed and the omentum, uterus, and ovaries
were manually delivered. When adherent omental metas-
tasis was present, the omentum was delivered through the
incision, and the remainder of the omentectomy was per-
formed by a traditional approach. The transverse colon
was delivered through the incision, inspected, and over-
sewn as necessary. Large ovarian masses were decom-
pressed at the abdominal incision to assist extraction. The
periumbilical Maylard incision was closed with a running
mass closure with a delayed absorbable monofilament
suture. A laparoscopic 5-mm Argon-Beam Coagulator
(ABC, ValleyLab, Boulder, CO) was used to coagulate
residual tumor in the pelvis, abdominal peritoneum, in-
testinal mesentery, and diaphragm. The ABC was used at
a setting of 50 watts to 70 watts and an argon gas flow
setting at 4 L per minute.
On postoperative day 1, patients were given bowel stim-
ulation with 30mL of milk of magnesia, started on a gen-
eral diet, and were discharged when fluid intake was
adequate. Patients were followed up in the office weekly
following surgery until chemotherapy was initiated. Che-
motherapy consisted of carboplatin and Taxol IV q21 days
for 6 cycles.
RESULTS
Median age was 60 years old (range, 51 to 77), and median
BMI was 25 kg/m
2 (range, 18 to 32). Nine of the 11
patients (91%) had medical comorbidities, and 8 of 11
patients (73%) had prior abdominal surgery.
Nine of 11 cases (82%) were successfully debulked lapa-
roscopically without conversion to laparotomy. Median
operative time was 2.5 hours (range, 2.2 to 3.5), and
median blood loss was 275 mL (range, 15 to 800). Median
ovarian size was 5 cm (range, 2 to 16), and median
omental metastasis was 14 cm (range, 3 to 40). All tumors
were debulked to 2 mL, and 45% had no residual dis-
ease. Stage was 1–3B, 7–3C, and 1–4. Median length of
stay was 1 day (range, 1 to 7). Median postoperative VAS
pain score (range, 0 to 8) was 4 (discomforting). Two of 11
patients (18%) had postoperative complications. One pa-
tient developed acute tubular necrosis that resolved spon-
taneously on postoperative day 3. A second patient de-
veloped pneumonia and required a 7-day hospital stay.
Two cases could not be completed laparoscopically and
were converted to laparotomy. The first patient in this
series had extensive omental metastasis. All of the remain-
ing patients with large omental metastasis were success-
fully completed laparoscopically. The second patient had
bulky metastasis surrounding the rectosigmoid.
Ca125 normalized after a median of 3 cycles of chemo-
therapy (range, 1 to 3). At a median follow-up of 1 year
(range, 0.5 to 1.9), all patients are alive with no evidence
of disease. One patient recurred at 1.2 yr and underwent
laparoscopic secondary debulking and chemotherapy and
is presently disease free.
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In a PubMed search, we were unable to locate any prior
trials on laparoscopic cytoreduction for primary stage 3/4
ovarian cancer. Krivak et al7 reported on hand-assisted
laparoscopy; however, only 6 of 25 patients had advanced
cancer and only 3 of the 6 (50%) were successfully de-
bulked. We have previously reported on laparoscopic
secondary cytoreductive surgery for recurrent ovarian
cancer.3 Of 36 patients, 94% were successfully debulked
laparoscopically. Since recurrence was discovered be-
cause of Ca125 elevation, most recurrent tumors were 2
cm and thus less bulky than our present series. Laparos-
copy has also been used in advanced ovarian cancer to
predict the chance of optimal cytoreduction at laparot-
omy8 and for second-look evaluation after laparotomy
cytoreduction and chemotherapy.9
Although we were unable to locate any prior trials on
laparoscopic cytoreduction for primary advanced ovarian
cancer, we can compare our results with the results of our
previous study on Maylard laparotomy cytoreduction. Of
31 patients with primary advanced ovarian cancer cytore-
duced via a Maylard laparotomy, cytoreduction to 2c m
residual disease was similar to that of our present series,
but operative time was 28% longer, length of stay was 4
times longer, and postoperative complications were in-
creased 61%. Also, it is interesting to compare our results
with “ultraradical” laparotomy cytoreduction. Eisenkop et
al,10 a major proponent of ultraradical laparotomy cytore-
duction, reported on 408 patients with primary stage 3C
ovarian cancer who underwent laparotomy cytoreduc-
tion. In this series, cytoreduction to no residual disease
was almost double our rate (86% vs 45%). However,
morbidity was significantly increased: operative time was
increased 20%, blood loss was tripled, length of stay was
10 times longer, and postoperative complications were
significantly increased, including a 3% mortality.
Of the multiple benefits of laparoscopic surgery, fewer
postoperative adhesions (decreased 60%)4 may be espe-
cially beneficial for primary advanced ovarian cancer.
Following cytoreduction and platinum/Taxol chemother-
apy for primary advanced ovarian cancer, 80% of patients
will go into remission. However, 75% of these tumors will
recur. Frequently, secondary cytoreduction is performed
at the time of recurrence.3,6 Fewer postoperative adhe-
sions following primary laparoscopic cytoreduction may
allow secondary cytoreduction to be performed more
safely and successfully.
CONCLUSION
We present the original series of laparoscopic cytoreduc-
tion for primary advanced ovarian cancer. Laparoscopic
cytoreduction was successful (82%) and resulted in mini-
mum morbidity (1-day hospital stay, minimal pain, 18%
complications). Because of our small sample size, addi-
tional studies are needed. If additional studies confirm our
results, prospective randomized controlled trials are
needed to compare laparoscopic and open cytoreduction
for primary stage 3/4 ovarian cancer to compare success,
morbidity, and survival.
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